A subcutaneous bispecific monoclonal antibody (CD20xCD3) T-cell engager that binds CD20 on malignant B cells and CD3 on endogenous T cells to form an immune synapse, activate TCR/CD3 signaling, and induce T-cell mediated cytotoxicity, resulting in depletion of CD20-positive lymphoma cells.
Bispecific CD20xCD3 monoclonal antibody that simultaneously binds CD20 on malignant B cells and CD3 on endogenous T cells to create an immune synapse, activate TCR/CD3 signaling, and drive T cell–mediated cytotoxic killing and depletion of CD20-positive lymphoma cells.
YES
DIRECT
Bispecific CD20xCD3 antibody bridges CD20+ cells to T cells, activating CD3 signaling to form an immune synapse and trigger perforin/granzyme-mediated killing of the CD20-expressing cells.
A subcutaneous bispecific monoclonal antibody (CD20xCD3) T-cell engager that binds CD20 on malignant B cells and CD3 on endogenous T cells to form an immune synapse, activate TCR/CD3 signaling, and induce T-cell mediated cytotoxicity, resulting in depletion of CD20-positive lymphoma cells.
Bispecific CD20xCD3 monoclonal antibody that simultaneously binds CD20 on malignant B cells and CD3 on endogenous T cells to create an immune synapse, activate TCR/CD3 signaling, and drive T cell–mediated cytotoxic killing and depletion of CD20-positive lymphoma cells.
NO
INDIRECT
Mosunetuzumab binds CD3ε on T cells to activate and redirect them to CD20+ B cells, forming an immune synapse. Activated T cells kill the CD20-expressing cells via perforin/granzyme-mediated cytotoxicity; CD3+ T cells are not the targets of killing.
A gene-modified, autologous T-cell therapy expressing a chimeric antigen receptor targeting CD19. Upon binding CD19 on B-lineage cells, CAR-T cells activate independently of the native TCR, expand, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity to clear CD19+ leukemic blasts, causing B-cell aplasia.
Autologous gene‑modified T cells expressing a CD19‑targeted chimeric antigen receptor bind CD19 on B‑lineage cells, triggering CAR signaling independent of the native TCR. This activates and expands the T cells, induces cytokine release, and mediates perforin/granzyme‑dependent cytotoxic killing of CD19+ leukemic blasts, resulting in depletion of malignant and normal B cells (B‑cell aplasia).
YES
DIRECT
CAR-T cells bind CD19 on target B cells, activate, and kill via perforin/granzyme-mediated cytolysis (and related apoptosis pathways).
Investigational apheresis-derived therapeutic immune cell product administered as a single IV infusion (dose-escalation 5.0×10^7 to 3.0×10^9 cells) for refractory/recurrent/metastatic digestive tract cancers; adoptive cellular immunotherapy intended to recognize a tumor-associated target protein and mediate T/NK-like cytotoxic killing of malignant cells.
Adoptive transfer of apheresis-derived immune effector cells that are expanded/activated ex vivo to recognize a tumor-associated target protein and kill malignant cells via T/NK cell–like cytotoxic mechanisms (e.g., perforin/granzyme-mediated lysis).
YES
DIRECT
Adoptively transferred immune effector cells recognize the tumor-associated target and directly lyse antigen-positive cells via T/NK cytotoxicity (perforin/granzyme-mediated apoptosis).
A CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that binds CD20 on B cells and CD3 on T cells to activate cytotoxic T cells and eliminate CD20+ lymphoma cells.
A CD20xCD3 bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, cross-linking and activating cytotoxic T cells to form immune synapses and lyse CD20-positive malignant B cells.
YES
DIRECT
CD20xCD3 bispecific antibody crosslinks T cells to CD20+ cells, activating cytotoxic T cells to deliver perforin/granzymes and lyse/apoptose the target cells.